Application of a catenary PBPK model to predict the disposition of "catch and release" anti-PCSK9 antibodies

被引:11
作者
Glassman, Patrick M. [1 ]
Balthasar, Joseph P. [1 ]
机构
[1] SUNY Buffalo, Univ Buffalo, Sch Pharm & Pharmaceut Sci, Dept Pharmaceut Sci, Buffalo, NY 14214 USA
关键词
Monoclonal antibodies; Physiologically-based pharmacokinetics (PBPK); Antibody engineering; NEONATAL FC-RECEPTOR; MEDIATED DRUG DISPOSITION; SERUM HALF-LIFE; PHARMACOKINETIC MODEL; MONOCLONAL-ANTIBODIES; IN-VIVO; IGG ANTIBODIES; SCALE-UP; 9; PCSK9; BINDING;
D O I
10.1016/j.ijpharm.2016.03.066
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The development of 'catch and release', or pH-sensitive, monoclonal antibodies (mAb) has become of interest to groups seeking to reduce the influence of target-mediated elimination on pharmacokinetics and pharmacodynamics. In this work, a catenary physiologically-based pharmacokinetic (PBPK) model is described to predict the pharmacokinetic benefit conferred by engineering mAbs for 'catch and release' binding. Our previously published PBPK model was adapted for consideration of the production and elimination of proprotein convertase subtilisin/kexin type 9 (PCSK9) in mice, and the model was then applied to predict the pharmacokinetics of anti-PCSK9 mAb with pH-stable (J10) and pH-sensitive binding U17). The model was able to generate reasonable predictions of both J10 and J17 plasma pharmacokinetics. For J10, mean (+/- standard deviation) predicted vs. observed areas under the plasma concentration curve (AUC(inf)) were: 217 (77.1) vs. 10(3) nM day (1 mg/kg), 1.14 x 10(3) (858) vs. 769 nM day (3 mg/kg), and 6.60 x 10(3) (5.58 x 10(3)) vs. 2.86 x 10(3) nM day (10 mg/kg), and for J17 the values were: 838 (161) vs. 818 nM day (1 mg/kg), 2.30 x 10(3) (441) vs. 2.57 x 10(3) nM day (3 mg/kg), and 8.42 x 10(3) (1.50 x 10(3)) vs. 9.17 x 10(3) nM day (10 mg/kg). Further simulations with the model predicted that target turnover and the magnitude of change in the complex dissociation rate constant between pH 7.4 and pH 6.0 are key determinants of the improvements in pharmacokinetics associated with 'catch and release' mAbs. The model described here may be useful for prediction of the pharmacokinetics of 'catch and release' mAbs directed against other targets. (C) 2016 Published by Elsevier B.V.
引用
收藏
页码:69 / 78
页数:10
相关论文
共 38 条
[1]   Application of PBPK modeling to predict monoclonal antibody disposition in plasma and tissues in mouse models of human colorectal cancer [J].
Abuqayyas, Lubna ;
Balthasar, Joseph P. .
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2012, 39 (06) :683-710
[2]   Cross-species Binding Analyses of Mouse and Human Neonatal Fc Receptor Show Dramatic Differences in Immunoglobulin G and Albumin Binding [J].
Andersen, Jan Terje ;
Daba, Muluneh Bekele ;
Berntzen, Goril ;
Michaelsen, Terje E. ;
Sandlie, Inger .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2010, 285 (07) :4826-4836
[3]  
BAXTER LT, 1995, CANCER RES, V55, P4611
[4]   The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A-Functional consequences of natural mutations and post-translational modifications [J].
Benjannet, Suzanne ;
Rhainds, David ;
Hamelin, Josee ;
Nassoury, Nasha ;
Seidah, Nabil G. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (41) :30561-30572
[5]   Effects of Charge on Antibody Tissue Distribution and Pharmacokinetics [J].
Boswell, C. Andrew ;
Tesar, Devin B. ;
Mukhyala, Kiran ;
Theil, Frank-Peter ;
Fielder, Paul J. ;
Khawli, Leslie A. .
BIOCONJUGATE CHEMISTRY, 2010, 21 (12) :2153-2163
[6]   Increasing Serum Half-life and Extending Cholesterol Lowering in Vivo by Engineering Antibody with pH-sensitive Binding to PCSK9 [J].
Chaparro-Riggers, Javier ;
Liang, Hong ;
DeVay, Rachel M. ;
Bai, Lanfang ;
Sutton, Janette E. ;
Chen, Wei ;
Geng, Tao ;
Lindquist, Kevin ;
Casas, Meritxell Galindo ;
Boustany, Leila M. ;
Brown, Colleen L. ;
Chabot, Jeffrey ;
Gomes, Bruce ;
Garzone, Pamela ;
Rossi, Andrea ;
Strop, Pavel ;
Shelton, Dave ;
Pons, Jaume ;
Rajpal, Arvind .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 287 (14) :11090-11097
[7]   Evaluation of a Catenary PBPK Model for Predicting the In Vivo Disposition of mAbs Engineered for High-Affinity Binding to FcRn [J].
Chen, Yang ;
Balthasar, Joseph P. .
AAPS JOURNAL, 2012, 14 (04) :850-859
[8]  
D'Argenio DZ., 2009, ADAPT 5 User's Guide: Pharmacokinetic/Pharmacodynamic Systems Analysis Software
[9]   Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn) [J].
Dall'Acqua, William F. ;
Kiener, Peter A. ;
Wu, Herren .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (33) :23514-23524
[10]   Monoclonal antibody clearance -: Impact of modulating the interaction of IgG with the neonatal Fc receptor [J].
Datta-Mannan, Amita ;
Witcher, Derrick R. ;
Tang, Ying ;
Watkins, Jeffry ;
Wroblewski, Victor J. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (03) :1709-1717